Sell Sheet: illumigene® C. difficile - Meridian Bioscience, Inc.

the Most CliniCAllY Definitive AssAY
for C. DIFFICILE testinG
Definitive Answers, ConfiDent results
• Fully comply with ASM guidelines
• Get the right result the first time
• Reduce healthcare costs associated with isolation, antibiotics
and outbreaks

ExcEEd Your currEnt C. DIFFICILE
tEsting PErformancE
• Fully comply with ASM guidelines for C. difficile testing 1
— Molecular testing and toxigenic culture–the onlY recommended
stand-alone option
• Molecular performance with illumigene ® C. difficile provides
increased sensitivity 2
Sensitivity
95.2%
— Proven accuracy through proficiency testing
• A new standard of patient care
EasE of usE
Specificity
95.3%
• Unlike our competition, no capital expense required
• Simplified procedure
• One test, one specimen
dEfinitivE answErs, confidEnt rEsults
• illumigene ® C. difficile provides definitive answers to ensure patients
receive the appropriate antibiotic therapy
— Helps guide therapy and isolation decisions
— Eliminates need for empiric therapy
• Refer to the C.difficile HAI models to see how illumigene ® C.difficile
can reduce healthcare costs related to isolation and length of stay
in your facility

Ordering Information
ILLUMI CDIFF rev. 04.2012
Product
illumipro-10 Incubator Reader
illumipro-10 Printer
illumipro-10 Keyboard
illumigene ®
illumigene ®
illumigene ®
Workstation
C. difficile Assay
External Controls C. difficile
For more information in the US,
contact a specialist at 1-888-763-6769.
www.meridianbioscience.com
Catalog #
610172
610173
610174
610169
280050
279920
REFERENCES
1. The following references were cited in the current ASM Guidelines for the Detection of Toxigenic Clostridium difficile:
i. Infect Control Hosp Epidemiol. 2010; 31(5):43155. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and
the Infectious Diseases Society of America (IDSA). Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH.
ii. J Clin Microbiol. 2010; 48(6):20826. Evaluation of the C.Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of
Clostridium difficile disease. Sharp SE, Ruden LO, Pohl JC, Hatcher PA, Jayne LM, Ivie WM.
iii. Am J Clin Pathol. 2010; 133(1):1079. Comparison of two rapid assays for Clostridium difficile Common antigen and a C. difficile toxin A/B assay with the cell culture neutralization assay. Reller ME, Alcabasa
RC, Lema CA, Carroll KC.
iv. J Clin Microbiol. 2010; 48(2):6035. C. Diff Quik Chek complete enzyme immunoassay provides a reliable firstline method for detection of Clostridium difficile in stool specimens. Quinn CD, Sefers SE,
Babiker W, He Y, Alcabasa R, Stratton CW, Carroll KC, Tang YW.
v. J Clin Microbiol. 2010 Feb;48(2):6068. Epub 2009 Dec 23. Evaluation of diagnostic tests for Clostridium difficile infection. Swindells J, Brenwald N, Reading N, Oppenheim B.
vi. Infectious Diseases of the Fetus and Newborn Infant. 2001, pp 12812. Remington, J.S., Klein, J.O. WB. Saunders Co., Philadelphia
2. illumigene ® C. difficile package insert, April 2011.